Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Cash from Operations of 197000000.0 for Q1 2026, down 18.67% year-over-year from 242237037.04 in Q1 2025, and down 97.34% quarter-over-quarter from 99829000.0 in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Cash from Operations (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has 14 years of Cash from Operations data on file, last reported at 197000000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 197000000.0, down 18.67% year-over-year; the trailing twelve-month figure through Mar 2026 was 497000000.0 (down 27.67% YoY), and the FY2025 annual result was 466000000.0, down 12.56% from the prior year.
- Cash from Operations eased to 197000000.0 in Q1 2026 per RARE's latest filing, from 99829000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 66995000.0 in Q3 2024 and troughed at 197000000.0 in Q1 2026.
- A 5-year average of 113674411.76 and a median of 99829000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 66.24% in 2022, then surged 43.16% in 2024.
- A 5-year view of Cash from Operations shows it stood at 90342000.0 in 2022, then gained by 6.91% to 84098000.0 in 2023, then rose by 5.69% to 79315000.0 in 2024, then fell by 25.86% to 99829000.0 in 2025, then slumped by 97.34% to 197000000.0 in 2026.
- Business Quant data shows RARE's Cash from Operations at 197000000.0 in Q1 2026, 99829000.0 in Q4 2025, and 91423000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ultragenyx Pharmaceutical | 2.77 Bn | 2.36 Bn | 106.00 Mn | -197.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -197.00 Mn |
| Mar 31, 2026 | -197.00 Mn |
| Dec 31, 2025 | -99.83 Mn |
| Dec 31, 2025 | -99.83 Mn |
| Sep 30, 2025 | -91.42 Mn |
| Sep 30, 2025 | -91.42 Mn |
| Jun 30, 2025 | -108.75 Mn |
| Jun 30, 2025 | -108.75 Mn |
| Mar 31, 2025 | -166.00 Mn |
| Mar 31, 2025 | -166.00 Mn |
| Dec 31, 2024 | -79.32 Mn |
| Dec 31, 2024 | -79.32 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Jun 30, 2024 | -76.96 Mn |
| Jun 30, 2024 | -76.96 Mn |
| Mar 31, 2024 | -190.73 Mn |
| Mar 31, 2024 | -190.73 Mn |
| Dec 31, 2023 | -84.10 Mn |
| Dec 31, 2023 | -84.10 Mn |